Apr 04, 2023 – Singapore Biotech Axcynsis Therapeutics Strengthens Scientific Team In Its Development Of Antibody Drug Conjugate Cancer Therapeutics 

Axcynsis Therapeutics is proud to announce the appointment of Professor Paul L. Herrling to its Scientific Advisory Board. The appointment strengthens the company’s scientific team in its development of Antibody Drug Conjugates (ADCs), an area touted to be a disruptive innovation in Cancer therapy.

Prof. Paul Herrling who’s experience spans Life Sciences, Vaccines, Oncology, Infectious Diseases, and Clinical Trials, is also a emeritus professor of Drug Discovery at the University of Basel, Switzerland, and has held multiple leadership positions at Novartis including Head of Global Research at Novartis Pharma. Prof. Herrling who previously held the position of Chairman of the board of the Novartis Institute for Tropical Diseases in Singapore, received his Ph.D. from the University of Zurich in 1975 and completed a post-doctoral fellowship at the UCLA Neuropsychiatric Institute.

“We are delighted and honoured to have Prof Herrling join our board of scientific advisors, as we will benefit greatly from his breadth of scientific experience and international scientific and business network,” said Dr. Zou, Founder and CEO of Axcynsis.

“I look forward to my work with Axcynsis and to contributing in any way I can to the exciting area of Antibody Drug Conjugates and cancer therapy,” said Prof. Herrling, “Some good progress has been made by the Axcynsis team, and I certainly hope we can move forward even further soon,” he added.


About Axcynsis Therapeutics Pte. Ltd.
Axcynsis Therapeutics Pte. Ltd. is a platform-based biotechnology company focusing on the development of Antibody Drug Conjugates (ADCs) to revolutionise cancer treatments. The Singapore biotech start-up leverages on proprietary technologies in its development of a robust pipeline of ADC candidates to address unmet medical needs for cancer treatment.

For all media queries, please contact: